Abstract
Cytokines and cytokine-induced nitric oxide (NO) play important roles in inflammatory glomerular diseases, and both platelet-derived growth factor and transforming growth factor-β inhibit cytokine-induced NO production. In this study, we demonstrated that a selective endothelin ET A receptor antagonist, BQ-485 (Hexahydro-1 H-azepinylcarbonyl-Leu- d-Trp- d-Trp-OH), reversed the inhibitory effect of platelet-derived growth factor on cytokine-induced NO production, but not that of transforming growth factor-β. Our findings suggest a difference between the inhibitory mechanisms of platelet-derived growth factor and transforming growth factor-β on cytokine-induced NO production.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
